PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1836299
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1836299
Next-Generation IVD market size was valued at US$ 98,789.12 Million in 2024, expanding at a CAGR of 5.4% from 2025 to 2032.
The Next-Generation In Vitro Diagnostics (IVD) market refers to advanced diagnostic technologies designed to provide faster, more accurate, and personalized disease detection and monitoring. These solutions leverage innovations such as molecular diagnostics, genomics, and advanced biomarkers to improve clinical decision-making and patient outcomes. Incorporating automation, digital integration, and point-of-care capabilities, next-generation IVD enables early diagnosis, targeted treatment, and efficient healthcare delivery across diverse medical fields, supporting the shift toward precision medicine and preventive healthcare approaches.
Next-Generation IVD Market- Market Dynamics
Increasing incidence of chronic diseases among aging population to propel market demand
The increasing prevalence of chronic diseases among the aging population is driving the demand for advanced diagnostic solutions. According to the World Health Organization, the global population aged 60 years and above is expected to reach 2.1 billion by 2050, highlighting the need for improved diagnostic tools. Besides, the integration of artificial intelligence and machine learning into diagnostic platforms is enhancing test accuracy and efficiency. However, the development and implementation of next-generation diagnostic technologies often involve significant investment, which can be a barrier for healthcare systems, especially in low-resource settings. On the contrary, there is a growing opportunity in emerging markets where healthcare infrastructure is expanding, and there is an increasing demand for advanced diagnostic solutions. Moreover, the shift towards personalized medicine, which tailors' treatment to individual genetic profiles, is creating demand for advanced diagnostic tools that can provide precise and actionable insights.
Next-Generation IVD Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.4% over the forecast period (2025-2032)
Based on Product segmentation, consumables was predicted to show maximum market share in the year 2024
Based on Type segmentation, molecular diagnostics was the leading Type in 2024
Based on Application segmentation, infectious diseases was the leading Application in 2024
On the basis of region, North America was the leading revenue generator in 2024
The Global Next-Generation IVD Market is segmented on the basis of Product, Type, Application, End User, and Region.
The market is divided into three categories based on Product: software, instruments, and consumables. The consumables segment is expected to hold the major market share during the forecast period. This is due to the recurring need for reagents, test kits, and other disposable components essential for conducting diagnostic tests, which drives consistent demand and revenue in the market.
The market is divided into five categories based on Application: infectious diseases, oncology/cancer, cardiology, diabetes, and others. Among these, the infectious diseases sector is expected to hold the major market share during the forecast period, driven by the ongoing need for rapid, accurate diagnosis and monitoring of infectious agents.
Next-Generation IVD Market- Geographical Insights
The North America region is expected to hold the largest market share, driven by advanced healthcare infrastructure, supportive regulations, and early adoption of cutting-edge diagnostic technologies. On the other hand, the Asia-Pacific region is projected to exhibit the fastest growth during the forecast period as healthcare investments rise and diagnostic access improves across developing economies.
Increasing demand for personalized, data-driven healthcare is spurring competition, leading firms to integrate next-gen molecular technologies, AI, and digital diagnostics into their offerings. Companies are enhancing molecular and sequencing-based platforms with automation and artificial intelligence to improve diagnostic accuracy and speed. Strategic partnerships and collaborations across biotech and tech sectors are becoming pivotal for expanding capabilities and market reach.
In June 2025, Revvity launched its first IVD Mimix reference standards, offering diagnostic labs reliable quality controls for next-generation sequencing and ddPCR assays. These FDA-compliant standards help labs monitor test performance, reduce errors, and improve cancer diagnosis accuracy.